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Abstract
Whipple’s disease is a rare cause of chronic diarrhea and abdominal pain that may be confused with inflam-
matory bowel disease. We report a Whipple’s case misdiagnosed as Crohn’s disease in which treatment with 
anti-tumor necrosis factor (anti-TNF) therapy led to nearly fatal progression. Lymph node tissue obtained dur-
ing laparotomy for suspected bowel necrosis stained dramatically with periodic acid–Schiff (PAS), and electron 
microscopy showed a bacterium consistent with Trophyrema whipplei. The patient made a remarkable recovery 
complicated only by cholestatic hepatitis, which was likely a treatment-associated inflammatory response. This 
case serves as a reminder that all granulomatous infections should be considered prior to initiation of anti-TNF 
therapies.  
Introduction
Whipple’s disease is a rare granulomatous infection of the gastrointestinal tract, with roughly 30 cases reported 
to the United States Centers for Disease Control each year. The causative agent is a fastidious, slow-growing, 
gram-positive actinomycete, Trophyrema whipplei, which was finally identified in the early 1990s using molecu-
lar biology techniques based on 16S ribosomal RNA PCR amplification.1,2 The illness is seen mostly in the fourth 
through sixth decades of life, typically presenting as chronic abdominal pain, diarrhea, weight loss, and joint 
complaints, with or without fevers. Pathogenesis of the infection includes invasion of the gastrointestinal mucosa, 
recruitment of macrophages to the lamina propria, and obstruction of local lymphatics, causing blunting of the 
small intestine villi and malabsorption/malnutrition. The bacteria can disseminate regionally from the small bowel 
to mesenteric lymph nodes, spleen, liver, and extraperitoneal organs including the joints, pleura, heart, and CNS. 
Untreated Whipple’s disease is a fatal infection; however, once diagnosed, Whipple’s disease is readily treated 
with ceftriaxone induction followed by prolonged oral trimethoprim/sulfamethoxazole therapy.3
It is common for patients with Whipple’s disease experiencing prominent joint complaints with mild gastrointes-
tinal tract symptoms to be initially misdiagnosed with inflammatory arthritides. In a recent large survey of con-
firmed cases, 50% of Whipple’s patients were initially treated with immunosuppressive agents including steroids 
(43%) and tumor necrosis factor (TNF)-antagonists (14%) for presumed inflammatory arthritis.4 Analogously, 
there is the potential to misdiagnose Whipple’s disease as inflammatory bowel disease, as chronic diarrhea with 
abdominal pain is a common presentation in gastroenterology clinics. Because Whipple’s disease is rare and 
lacks a convenient diagnostic test, it may not be considered in the differential diagnosis for individual patients. 
Because TNF-antagonists are highly effective for treating inflammatory bowel diseases, including Crohn’s dis-
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ease, it is foreseeable that some Whipple’s patients misdiag-
nosed with inflammatory bowel disease will receive anti-TNF 
therapy. We report the first known example of this clinical 
scenario and the severe progression of Whipple’s disease 
that developed while on anti-TNF therapy.
Case Report
Our patient is a 69-year-old female with a past history of hypo-
thyroidism, degenerative joint disease, and restless legs syn-
drome admitted through the emergency room with 2.5 years 
of waxing and waning abdominal pain, diarrhea, fatigue, and 
weight loss. Upper endoscopy at an outside medical center 
1 year prior to admission showed patchy erythema in the 
duodenum. Biopsies showed villous blunting; celiac serolo-
gies were negative. Three months after the endoscopy ,she 
was admitted to a local hospital with diarrhea, abdominal 
pain, and dizziness. Video capsule endoscopy showed ul-
cerations in the small bowel consistent with Crohn’s disease. 
An anti-Saccharomyces cerevisiae antibody (ASCA) was 
positive. She was started on mesalamine and budesonide for 
presumed Crohn’s disease. That therapy did not control her 
symptoms, so the mesalamine was changed to adalimumab, 
a monoclonal antibody specific for TNF-alpha.  
Five months later, and 5 months prior to her current admis-
sion, she was readmitted to the local hospital with weakness, 
fatigue, nausea, vomitting, diarrhea, and weight loss. CT 
evaluation was remarkable for abdominal lymphadenopathy. 
A lymph node sampled by CT-guided biopsy showed granu-
lomata with rare fungal-like organisms suggestive of histo-
plasmosis. Budesonide was stopped and prednisone ther-
apy was initiated, presumably because her diarrheal symp-
toms were attributed to a flare of Crohn’s disease. She was 
prescribed itraconazole, but she took this for only 2 weeks 
due to financial issues. Her last dose of adalimumab was 
approximately 1 month prior to admission to our hospital.  
The patient presented to our emergency room with com-
plaint of diarrhea, weakness, and “just not feeling right.” On 
admission the patient was strikingly cachectic in appear-
ance, weighing 40.7 kg (body mass index 16.2); temper-
ature 35.0°C, blood pressure 96/56 mmHg, heart rate 72 
bpm, respiratory rate 16 bpm, and O2 saturation 100% on 
room air. Her abdomen was distended, soft, and minimally 
tender to palpation, with hypoactive bowel sounds. The re-
mainder of her exam was unremarkable. Admission labs 
were grossly abnormal, especially albumin 1.4 gm/dL (nor-
mal: 3.5–5.0) and bicarbonate 12 mmol/L (normal: 22–29; 
see Table 1). Her admission non-contrast CT scan showed 
marked distention of the colon with multiple air-fluid levels. 
There were multiple soft tissue masses within the mesentery 
and retroperitoneal lymphadenopathy. A contrast CT scan 
was repeated 19 hours later because of worsening acido-
sis and hypotension. It showed the bulky retroperitoneal 
and mesenteric adenopathy, diffuse thickening of the en-
tire small bowel from the duodenum to the terminal ileum, 
and pneumatosis intestinalis (Figure 1). Concern for bowel 
compromise led to an emergent exploratory laparotomy. The 
bowel was intact with a pasty exudate covering the bowel 
and peritoneal surfaces. A 3 x 2-cm mesenteric lymph node 
was resected for pathology. Intraoperative brushings and 
frozen sections sent to surgical pathology showed granulo-
matous disease (Figure 2A). Acid-fast bacteria (AFB) and 
Grocott’s methenamine silver (GMS) stains were negative for 
acid-fast bacilli or fungi in brushings and lymph node tissue. 
The patient’s T-spot and Histoplasma capsulatum H-band 
M-band/complement fixation/urine antigen were negative. 
Based on her clinical history, the infectious disease service 
requested a periodic acid–Schiff (PAS) stain on lymph node 
tissue, which was positive (Figure 2B). Electron microscopy 
Table 1. Admission Laboratory Values
Laboratory Parameter Admission Values Normal Values
Sodium 138 mmol/L 135–145 mmol/L
Potassium 2.9 mmol/L* 3.5–5.5 mmol/L
Chloride 115 mmol/L* 98–108 mmol/L
Bicarbonate 12 mmol/L* 22–29 mmol/L
Urea nitrogen 35 mg/dL 5–20 mg/dL
Creatinine 1.5 mg/dL 0.6–1.4 mg/dL
Glucose 88 mg/dL 70–99 mg/dL
Calcium 6.3 mg/dL 8.5–10.5 mg/dL
Albumin 1.4 gm/dL* 3.5–5.0 gm/dL
Protein 4.8 gm/dL* 6.7–8.6 gm/dL
Total bilirubin 0.3 mg/dL 0.0–1.0 mg/dL
Alkaline phosphatase 87 U/L 25–125 U/L
AST 20 U/L 25–45 U/L
ALT 14 U/L 0–50 U/L
White blood cells 10.2 k/mm3 4.5–11.5 k/mm3
Hemoglobin 9.3 g/dL* 12–15 g/dL
Platelets 346 k/mm3 150–450 k/mm3
*Abnormal values. ALT = alanine aminotransferase; AST = aspartate aminotransferase.
Figure 1. CT scan of the abdomen with lymphadenopathy (rulers), abnor-
mal mesenteric soft tissue (*), thickened small bowel wall (small arrow), 
and pneumatosis intestinalis (large arrows).
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demonstrated aggregates of rod-shaped bacteria consis-
tent with Tropheryma whipplei (Figure 2C). There was no 
evidence of malignancy on histopathology or flow cytometry.
The patient was treated with ceftriaxone 2 gm daily for 2 
weeks, followed by oral trimethroprim/sulfamethoxazole 
therapy, dose-adjusted for mild renal insufficiency to 400/80 
mg orally 3 times daily. The patient recovered dramatically. 
She had a transient increase in alkaline phosphatase from 
its admission value of 87 U/L to a peak value of 525 U/L at 
3 weeks into antibiotic therapy, dropping down to 244 U/L 
at 4 weeks, and 204 U/L at 6 months of antibiotic therapy. A 
4-month follow-up CT scan showed a roughly 50% decrease 
in the size of all intraperitoneal lesions. Her lab abnormalities 
of anemia, acidosis, and hypoalbuminemia resolved. Four 
months after discharge, her weight was 54.9 kg, up from 
40.7 kg, close to her baseline weight 3 years earlier. Her di-
arrhea and joint pains resolved; her only residual complaint 
was her previously diagnosed restless legs syndrome.
Discussion
While there are several case reports of Whipple’s disease 
patients initially misdiagnosed with inflammatory arthritides 
and receiving TNF-antagonist therapies,5–9 to our knowledge 
this is the first reported case of a patient initially misdiag-
nosed with Crohn’s disease. Our patient had a severe case 
of Whipple’s disease due to either the 10-month duration of 
anti-TNF therapy preceding Whipple’s diagnosis, a signifi-
cant infection at the time of anti-TNF therapy initiation, or 
possibly both. Because the patient’s diarrhea and abdominal 
pain syndrome resolved completely with ceftriaxone followed 
by trimethoprim/sulfamethoxazole, it is highly unlikely that 
she has underlying Crohn’s disease.
  
Though difficult to prove, it is generally thought that anti-
TNF therapy worsens the clinical course of Whipple’s dis-
ease. A study of non-steroidal anti-inflammatory drugs ver-
sus conventional immunosuppression (corticosteroids, aza-
thioprine, methotrexate, etc.) in Whipple’s patients initially 
treated for inflammatory arthritis showed that immunosup-
pressive therapy accelerated the disease in the form of ear-
lier development of diarrhea.10 Our patient’s clinical course 
is consistent with that general impression. Histopathology 
suggests that macrophages are critical in the host immune 
response to Trophyrema whipplei infections. TNF-alpha is 
critical for macrophage killing of intracellular pathogens,11,12 
and has been shown to facilitate granuloma formation for 
the containment of intracellular pathogens such as Myco-
bacterium and Histoplasma.13,14 Disruption of granuloma 
formation is one hypothesis for the infectious complications 
of anti-TNF therapies.  
 
An interesting feature of our patient’s clinical course was a 
dramatic asymptomatic elevation in her alkaline phospha-
tase level after starting antibiotic therapy. Based on the ex-
tent of infection in her abdomen and hepatomegaly seen 
on CT, it is possible that the liver was also involved with the 
infection. Alternatively, treatment-induced inflammatory 
syndromes can be seen in Whipple’s disease patients.15 Our 
patient’s cholestatic liver injury may be a treatment-induced 
inflammatory syndrome. Her alkaline phosphatase con-
tinued to decline through 6 months of trimethoprim/sulfa-
methoxazole therapy, largely ruling out drug-related toxicity. 
However, the alkaline phosphatase was never fractionated, 
gamma-glutamyl transferase was never obtained, and a liver 
biopsy was not performed, so the true etiology cannot be 
proven.  
Advent of non-invasive endoscopy (video capsule) and sero-
logic testing for inflammatory bowel diseases (e.g., the Pro-
metheus® IBD7 panel [Prometheus Laboratories, Inc., San 
Diego, CA]) has the potential for non-histopathology–based 
Figure 2. (A) H&E staining of peritoneal cavity brushings (200 x magnification). (B) PAS staining of mesenteric lymph node tissue (200 x magnification). 
(C) Electron microscopy of lymph node tissue (43,600 x magnification). Yellow arrow highlights a rod-shaped bacterium consistent with Trophyrema whipplei.
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diagnosis of inflammatory bowel diseases. However, as this 
case report demonstrates, a non-histology–based diagnostic 
approach is problematic. There is a long differential diagno-
sis for small bowel ulcerations seen on capsule endoscopy. 
Positive serologic testing for inflammatory bowel disease is 
helpful in cases with a high pre-test probability, and can be 
helpful in distinguishing between Crohn’s disease and ul-
cerative colitis, but it is not diagnostic of either disease. A 
retrospective study in a pediatric abdominal pain/diarrhea/
weight loss cohort showed that the IBD7 panel had a posi-
tive predictive value of 63%.16 In our case, a non-diagnostic 
EGD duodenal biopsy (without PAS staining) was followed 
up by video endoscopy and serology to give an errant diag-
nosis of Crohn’s disease. Even with biopsy-based diagnosis 
of inflammatory bowel disease, there are overlapping his-
topathlogy findings in Crohn’s disease (non-caseating granu-
lomatous inflammation) and Whipple’s disease (histiocytic/
granulomatous infection). PAS stains on biopsy specimens 
are simple and inexpensive, but they must be specifically 
requested in most hospitals on biopsy specimens to exclude 
the presence of histiocytic or granulomatous inflammation to 
rule out Whipple’s disease. Patients presenting with abdomi-
nal pain/diarrhea syndromes in their fourth to sixth decades 
should have PAS stains performed on anti-TNF therapies.
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